Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

614
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
614
Hepatic Portal System01:21

Hepatic Portal System

1.5K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
1.5K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

46.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.1K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

86
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
86

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large Language Models Accurately Identify People Who Inject Drugs From Infectious Diseases Discharge Summaries in an Australian Hospital.

Drug and alcohol review·2026
Same author

Corrigendum to: Factors associated with delayed diagnosis of hepatitis B in southeastern Sydney.

Public health research & practice·2026
Same author

Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial.

JAMA psychiatry·2026
Same author

Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use: the SHARP-P study.

The International journal on drug policy·2026
Same author

New-onset diabetes following SARS-CoV-2 infection in the Omicron era: a matched cohort study.

International journal of epidemiology·2026
Same author

Interventions to improve testing, linkage to care, and treatment for hepatitis C infection in prison: a systematic review and meta-analysis.

The International journal on drug policy·2026

Related Experiment Video

Updated: Jul 15, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.2K

Hepatitis C.

Marianne Martinello1, Sunil S Solomon2, Norah A Terrault3

  • 1Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; Department of Infectious Diseases, Prince of Wales Hospital, Sydney, NSW, Australia.

Lancet (London, England)
|September 23, 2023
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) elimination requires improved screening, treatment access, and prevention. Direct-acting antivirals offer hope, but broader public health strategies are crucial for global HCV eradication by 2030.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.8K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.2K

Related Experiment Videos

Last Updated: Jul 15, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.2K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.8K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.2K

Area of Science:

  • Virology
  • Hepatology
  • Public Health

Background:

  • Hepatitis C virus (HCV) causes liver damage, cirrhosis, and cancer.
  • Global HCV elimination by 2030 is a WHO goal.
  • Millions remain infected, with significant annual mortality.

Purpose of the Study:

  • To review the current status of HCV infection globally.
  • To highlight the impact of direct-acting antiviral (DAA) therapies.
  • To identify key strategies needed for HCV elimination.

Main Methods:

  • Review of epidemiological data on HCV prevalence and mortality.
  • Assessment of the clinical impact of direct-acting antiviral therapies.
  • Analysis of public health interventions for HCV control.

Main Results:

  • Direct-acting antivirals have transformed HCV treatment.
  • Despite progress, substantial global HCV burden persists.
  • Significant gaps exist in screening, linkage to care, and treatment coverage.

Conclusions:

  • Achieving HCV elimination requires a multi-faceted approach.
  • Enhanced screening, care linkage, and prevention are critical.
  • Sustained efforts are needed to meet the 2030 elimination target.